Carcinoma, Islet Cell: all 33 studies
Page 1 of 1. Open to participants first (1), then studies with results posted, then the rest; newest registration first within each.
- Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic DisordersRecruitingNCT00830557
- Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic OriginTerminatedNCT03736720Phase 2Results posted
- FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine CarcinomasTerminatedNCT03042780Phase 2Results posted
- Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by SurgeryCompletedNCT02893930Phase 2Results posted
- Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney CancerTerminatedNCT02273752Phase 2Results posted
- Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine TumorsCompletedNCT02259725Phase 2Results posted
- Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by SurgeryCompletedNCT02101918Phase 2Results posted
- Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With SurgeryTerminatedNCT02031536Phase 2Results posted
- Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine TumorsCompletedNCT01824875Phase 2Results posted
- Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine TumorsCompletedNCT01525082Phase 2Results posted
- Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By SurgeryCompletedNCT01465659Phase 1/2Results posted
- Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell CancerCompletedNCT01010126Phase 2Results posted
- Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine CancerCompletedNCT00454363Phase 2Results posted
- A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic Islet Cell TumorsTerminatedNCT00428597Phase 3Results posted
- A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.CompletedNCT00428220Not applicableResults posted
- Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to ChemotherapyCompletedNCT00363051Phase 2Results posted
- Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine TumorsCompletedNCT00131911Phase 2Results posted
- RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine CarcinomaCompletedNCT00113360Phase 2Results posted
- Temsirolimus in Treating Patients With Metastatic Neuroendocrine CarcinomaCompletedNCT00093782Phase 2Results posted
- Assessment of What Patients and Healthcare Providers ValueCompletedNCT04483349
- Diagnosis of PCL With EUS-FNA and Cross-sectional Imaging - A Report of AccuracyStatus unknownNCT03884179
- A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET)CompletedNCT02806648Phase 2
- Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase IICompletedNCT02230176Phase 2
- Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine TumorsWithdrawnNCT02108782Phase 2
- Potential Molecular Predictors of Response to Novel Therapies in Metastatic Pancreatic Neuroendocrine TumorsCompletedNCT01603004
- Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine CarcinomaCompletedNCT01204476Phase 1
- Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid TumorsCompletedNCT01155258Phase 1
- Everolimus and Vatalanib in Treating Patients With Advanced Solid TumorsCompletedNCT00655655Phase 1
- Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine TumorsWithdrawnNCT00227773Phase 2
- Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine TumorsTerminatedNCT00084461Phase 2
- Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine TumorsCompletedNCT00075439Phase 2
- Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuCompletedNCT00004074Phase 1
- Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation TherapyWithdrawnNCT00003514Phase 2